Selection was also based on the presence of Kirsten rat sarcoma virus (KRAS) mutations in all three cell lines, as KRAS mutations are highly prevalent in rectal cancers and we assumed that MEK1/2 inhibition would be more potent in models with activated RAS-MAPK signaling.9 The gene discussed is KRAS; the disease is rectal cancer.